A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion for the Treatment of Postoperative Pain.

Trial Profile

A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion for the Treatment of Postoperative Pain.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2015

At a glance

  • Drugs KAI 1678 (Primary) ; Ketorolac
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors KAI Pharmaceuticals
  • Most Recent Events

    • 26 Mar 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 26 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Nov 2009 Official title, actual start date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top